Generic placeholder image

Cardiovascular & Hematological Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5257
ISSN (Online): 1875-6182

Research Article

Evaluation of Enhanced Cytotoxicity Effect of Repurposed Drug Simvastatin/Thymoquinone Combination against Breast Cancer Cell Line

Author(s): Pallavi Kumari* and Shweta Dang*

Volume 22, Issue 3, 2024

Published on: 27 October, 2023

Page: [348 - 366] Pages: 19

DOI: 10.2174/0118715257259037231012182741

Price: $65

Open Access Journals Promotions 2
Abstract

Introduction: Repurposing of drugs for their anticancer potential is gaining a lot of importance in drug discovery.

Aims: The present study aims to explore the potential of Simvastatin (SIM), a drug used in the treatment of high cholesterol, and Thymoquinone (Nigella Sativa) (THY) for its anti-cancer activity on breast cancer cell lines. Thymoquinone is reported to have many potential medicinal properties exhibiting antioxidant, antiinflammatory, anti-cancer, activities like inhibition of tissue growth and division.

Methods: In this analysis, we explored the inhibitory effects of the combination of Simvastatin ad Thymoquinone on two breast cancer cell lines viz MCF-7 and MDA-MB-231 cells. The combined effect of Simvastatin and Thymoquinone on Cell viability, Colony formation, Cell migration, and orientation of more programmed cell death in vitro was studied. Cell cycle arrest in the G2/M phase was concomitant with the combined effect of SIM and THY persuading apoptosis and generating reactive oxygen species (ROS).

Results: The cell cycle arrest with combined treatment was observed that only 1.8% and 1.1% cells gated in G2/M phase in MCF-7 & MDA-MB-231 cell. An increased apoptosis was observed when cells were treated in combination which was about 76.20% and 58.15% respectively for MCF-7 and MDA-MB-231 cells.

Conclusion: It was concluded that the combined effect of simvastatin and thymoquinone stimulates apoptosis in breast cancer cells.

Keywords: Breast cancer, drug repurposing, drug combination, cell cycle arrest, cell apoptosis, simvastatin, mevalonate pathway.

Graphical Abstract
[1]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Vaidya, F.U.; Sufiyan Chhipa, A.; Mishra, V.; Gupta, V.K.; Rawat, S.G.; Kumar, A.; Pathak, C. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep., 2022, 5(12), e1291.
[http://dx.doi.org/10.1002/cnr2.1291] [PMID: 33052041]
[3]
Qin, S.; Jiang, J.; Lu, Y.; Nice, E.C.; Huang, C.; Zhang, J.; He, W. Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduct. Target. Ther., 2020, 5(1), 228.
[http://dx.doi.org/10.1038/s41392-020-00313-5] [PMID: 33028808]
[4]
Pammolli, F.; Magazzini, L.; Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov., 2011, 10(6), 428-438.
[http://dx.doi.org/10.1038/nrd3405] [PMID: 21629293]
[5]
Su, M.; Zhang, Q.; Bai, X.; Wu, C.; Li, Y.; Mossialos, E.; Mensah, G.A.; Masoudi, F.A.; Lu, J.; Li, X.; Salas-Vega, S.; Zhang, A.; Lu, Y.; Nasir, K.; Krumholz, H.M.; Jiang, L. Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. Lancet, 2017, 390(10112), 2559-2568.
[http://dx.doi.org/10.1016/S0140-6736(17)32476-5] [PMID: 29102087]
[6]
Bedard, P.L.; Hyman, D.M.; Davids, M.S.; Siu, L.L. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet, 2020, 395(10229), 1078-1088.
[http://dx.doi.org/10.1016/S0140-6736(20)30164-1] [PMID: 32222192]
[7]
Pushpakom, S.; Iorio, F.; Eyers, P.A.; Escott, K.J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, T.; Latimer, J.; McNamee, C.; Norris, A.; Sanseau, P.; Cavalla, D.; Pirmohamed, M. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov., 2019, 18(1), 41-58.
[http://dx.doi.org/10.1038/nrd.2018.168] [PMID: 30310233]
[8]
Shai, S. Evaluating the Therapeutic Potential of Penfluridol in Head and Neck Cancer 2023.
[9]
Maxmen, A. Busting the billion-dollar myth: how to slash the cost of drug development. Nature, 2016, 536(7617), 388-390.
[http://dx.doi.org/10.1038/536388a] [PMID: 27558048]
[10]
Bertolini, F.; Sukhatme, V.P.; Bouche, G. Drug repurposing in oncology-patient and health systems opportunities. Nat. Rev. Clin. Oncol., 2015, 12(12), 732-742.
[http://dx.doi.org/10.1038/nrclinonc.2015.169] [PMID: 26483297]
[11]
Gupta, R.; Gupta, S.; Antonios, B.; Ghimire, B.; Jindal, V.; Deol, J.; Gaikazian, S.; Huben, M.; Anderson, J.; Stender, M.; Jaiyesimi, I. Therapeutic landscape of advanced HER2-positive breast cancer in 2022. Med. Oncol., 2022, 39(12), 258.
[http://dx.doi.org/10.1007/s12032-022-01849-y] [PMID: 36224475]
[12]
Murai, T. Cholesterol lowering: role in cancer prevention and treatment. Biol. Chem., 2015, 396(1), 1-11.
[http://dx.doi.org/10.1515/hsz-2014-0194] [PMID: 25205720]
[13]
Tobert, J.A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov., 2003, 2(7), 517-526.
[http://dx.doi.org/10.1038/nrd1112] [PMID: 12815379]
[14]
Ehmsen, S.; Pedersen, M.H.; Wang, G.; Terp, M.G.; Arslanagic, A.; Hood, B.L.; Conrads, T.P.; Leth-Larsen, R.; Ditzel, H.J. Increased cholesterol biosynthesis is a key characteristic of breast cancer stem cells influencing patient outcome. Cell Rep., 2019, 27(13), 3927-3938.e6.
[http://dx.doi.org/10.1016/j.celrep.2019.05.104] [PMID: 31242424]
[15]
Shojaei, S.; Alizadeh, J.; Thliveris, J.; Koleini, N.; Kardami, E.; Hatch, G.M.; Xu, F.; Hombach-Klonisch, S.; Klonisch, T.; Ghavami, S. Statins: a new approach to combat temozolomide chemoresistance in glioblastoma. J. Investig. Med., 2018, 66(8), 1083-1087.
[http://dx.doi.org/10.1136/jim-2018-000874] [PMID: 30368483]
[16]
Wang, T.; Seah, S.; Loh, X.; Chan, C.W.; Hartman, M.; Goh, B.C.; Lee, S.C. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget, 2016, 7(3), 2532-2544.
[http://dx.doi.org/10.18632/oncotarget.6304] [PMID: 26565813]
[17]
Woo, C.C.; Loo, S.Y.; Gee, V.; Yap, C.W.; Sethi, G.; Kumar, A.P.; Benny Tan, K.H. Anticancer activity of thymoquinone in breast cancer cells: Possible involvement of PPAR-γ pathway. Biochem. Pharmacol., 2011, 82(5), 464-475.
[http://dx.doi.org/10.1016/j.bcp.2011.05.030] [PMID: 21679698]
[18]
Armutcu, F.; Akyol, S.; Akyol, O. The interaction of glutathione and thymoquinone and their antioxidant properties. Electron. J. Gen. Med., 2018, 15(4)
[19]
Woo, C.C.; Kumar, A.P.; Sethi, G.; Tan, K.H.B. Thymoquinone: Potential cure for inflammatory disorders and cancer. Biochem. Pharmacol., 2012, 83(4), 443-451.
[http://dx.doi.org/10.1016/j.bcp.2011.09.029] [PMID: 22005518]
[20]
Asaduzzaman Khan, M.; Tania, M.; Fu, S.; Fu, J. Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget, 2017, 8(31), 51907-51919.
[http://dx.doi.org/10.18632/oncotarget.17206] [PMID: 28881699]
[21]
Mokhtari, R.B.; Homayouni, T.S.; Baluch, N.; Morgatskaya, E.; Kumar, S.; Das, B.; Yeger, H. Combination therapy in combating cancer. Oncotarget, 2017, 8(23), 38022-38043.
[http://dx.doi.org/10.18632/oncotarget.16723] [PMID: 28410237]
[22]
Kumari, P.; Dang, S. Dual drug loaded nanostructured lipid carrier for cytotoxic effect against breast cancer - a drug repurposing approach. Surf. Interfaces, 2023, 40, 103138.
[http://dx.doi.org/10.1016/j.surfin.2023.103138]
[23]
Rai, Y.; Pathak, R.; Kumari, N.; Sah, D.K.; Pandey, S.; Kalra, N.; Soni, R.; Dwarakanath, B.S.; Bhatt, A.N. Mitochondrial biogenesis and metabolic hyperactivation limits the application of MTT assay in the estimation of radiation induced growth inhibition. Sci. Rep., 2018, 8(1), 1531.
[http://dx.doi.org/10.1038/s41598-018-19930-w] [PMID: 29367754]
[24]
Zhang, N.; Fu, J.N.; Chou, T.C. Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. Am. J. Cancer Res., 2015, 6(1), 97-104.
[PMID: 27073727]
[25]
Syed Abdul Rahman, S.N.; Abdul Wahab, N.; Abd Malek, S.N. in vitro morphological assessment of apoptosis induced by antiproliferative constituents from the rhizomes of Curcuma zedoaria. Evid. Based Complement. Alternat. Med., 2013, 2013, 1-14.
[http://dx.doi.org/10.1155/2013/257108] [PMID: 23762112]
[26]
Yadav, S.S.; Prasad, C.B.; Prasad, S.B.; Pandey, L.K.; Singh, S.; Pradhan, S.; Narayan, G. Anti-tumor activity of staurosporine in the tumor microenvironment of cervical cancer: An in vitro study. Life Sci., 2015, 133, 21-28.
[http://dx.doi.org/10.1016/j.lfs.2015.04.019] [PMID: 26006035]
[27]
Freitas, J.T.; Jozic, I.; Bedogni, B. Wound healing assay for melanoma cell migration. Methods Mol. Biol., 2021, 2265, 65-71.
[28]
Wu, X.; Liu, P.C.; Liu, R.; Wu, X. Dual AO/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med. Sci. Monit. Basic Res., 2015, 21, 15-20.
[http://dx.doi.org/10.12659/MSMBR.893327] [PMID: 25664686]
[29]
Kwon, J.H.; Kim, J.H.; Ryu, D.S.; Lee, H.J.; Lee, D.S. Anticancer effect of the ethyl acetate fraction from Orostachys japonicus on MDA-MB-231 human breast cancer cells through extensive induction of apoptosis, cell cycle arrest, and antimetastasis. Evid. Based Complement. Alternat. Med., 2019, 2019, 1-10.
[http://dx.doi.org/10.1155/2019/8951510] [PMID: 31781282]
[30]
Dziedzic, A.; Kubina, R.; Kabała-Dzik, A.; Tanasiewicz, M. Induction of cell cycle arrest and apoptotic response of head and neck squamous carcinoma cells (Detroit 562) by caffeic acid and caffeic acid phenethyl ester derivative. Evid. Based Complement. Alternat. Med., 2017, 2017, 1-10.
[http://dx.doi.org/10.1155/2017/6793456] [PMID: 28167973]
[31]
Srivastava, V.; Wani, M.Y.; Al-Bogami, A.S.; Ahmad, A. Piperidine based 1,2,3-triazolylacetamide derivatives induce cell cycle arrest and apoptotic cell death in Candida auris. J. Adv. Res., 2021, 29, 121-135.
[http://dx.doi.org/10.1016/j.jare.2020.11.002] [PMID: 33842010]
[32]
Lee, S.O.; Joo, S.H.; Kwak, A.W.; Lee, M.H.; Seo, J.H.; Cho, S.S.; Yoon, G.; Chae, J.I.; Shim, J.H. Podophyllotoxin induces ROS-Mediated apoptosis and cell cycle arrest in human colorectal cancer cells via p38 MAPK signaling. Biomol. Ther. (Seoul), 2021, 29(6), 658-666.
[http://dx.doi.org/10.4062/biomolther.2021.143] [PMID: 34642263]
[33]
Kwak, A.W.; Lee, M.J.; Lee, M.H.; Yoon, G.; Cho, S.S.; Chae, J.I.; Shim, J.H. The 3-deoxysappanchalcone induces ROS-mediated apoptosis and cell cycle arrest via JNK/p38 MAPKs signaling pathway in human esophageal cancer cells. Phytomedicine, 2021, 86, 153564.
[http://dx.doi.org/10.1016/j.phymed.2021.153564] [PMID: 33895649]
[34]
Wen, L.P.; Fahrni, J.A.; Troie, S.; Guan, J.L.; Orth, K.; Rosen, G.D. Cleavage of focal adhesion kinase by caspases during apoptosis. J. Biol. Chem., 1997, 272(41), 26056-26061.
[http://dx.doi.org/10.1074/jbc.272.41.26056] [PMID: 9325343]
[35]
Al-Asmari, A.K.; Albalawi, S.M.; Athar, M.T.; Khan, A.Q.; Al-Shahrani, H.; Islam, M. Moringa oleifera as an anti-cancer agent against breast and colorectal cancer cell lines. PLoS One, 2015, 10(8), e0135814.
[http://dx.doi.org/10.1371/journal.pone.0135814] [PMID: 26288313]
[36]
Gherghi, I.; Girousi, S.T.; Voulgaropoulos, A.N.; Tzimou-Tsitouridou, R. Study of interactions between DNA-ethidium bromide (EB) and DNA-acridine orange (AO), in solution, using hanging mercury drop electrode (HMDE). Talanta, 2003, 61(2), 103-112.
[http://dx.doi.org/10.1016/S0039-9140(03)00238-8] [PMID: 18969168]
[37]
Mogheri, F.; Jokar, E.; Afshin, R.; Akbari, A.A.; Dadashpour, M.; Firouzi-amandi, A.; Serati-Nouri, H.; Zarghami, N. Co-delivery of metformin and silibinin in dual-drug loaded nanoparticles synergistically improves chemotherapy in human non-small cell lung cancer A549 cells. J. Drug Deliv. Sci. Technol., 2021, 66, 102752.
[http://dx.doi.org/10.1016/j.jddst.2021.102752]
[38]
Bai, F.; Yu, Z.; Gao, X.; Gong, J.; Fan, L.; Liu, F. Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p. Aging, 2019, 11(10), 3198-3219.
[http://dx.doi.org/10.18632/aging.101974] [PMID: 31138773]
[39]
Spampanato, C.; De Maria, S.; Sarnataro, M.; Giordano, E.; Zanfardino, M.; Baiano, S.; Cartenì, M.; Morelli, F. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int. J. Oncol., 2012, 40(4), 935-941.
[http://dx.doi.org/10.3892/ijo.2011.1273] [PMID: 22134829]
[40]
Darakhshan, S.; Bidmeshki Pour, A.; Hosseinzadeh Colagar, A.; Sisakhtnezhad, S. Thymoquinone and its therapeutic potentials. Pharmacol. Res., 2015, 95-96, 138-158.
[http://dx.doi.org/10.1016/j.phrs.2015.03.011] [PMID: 25829334]
[41]
Sánchez, C.A.; Rodríguez, E.; Varela, E.; Zapata, E.; Páez, A.; Massó, F.A.; Montaño, L.F.; López-Marure, R. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest., 2008, 26(7), 698-707.
[http://dx.doi.org/10.1080/07357900701874658] [PMID: 18608208]
[42]
Gali-Muhtasib, H.; Ocker, M.; Kuester, D.; Krueger, S.; El-Hajj, Z.; Diestel, A.; Evert, M.; El-Najjar, N.; Peters, B.; Jurjus, A.; Roessner, A.; Schneider-Stock, R. Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J. Cell. Mol. Med., 2008, 12(1), 330-342.
[http://dx.doi.org/10.1111/j.1582-4934.2007.00095.x] [PMID: 18366456]
[43]
Chen, M.; Kim, B.; Robertson, N.; Mondal, S.K.; Medarova, Z.; Moore, A. Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells. Front. Mol. Biosci., 2023, 10, 1179343.
[http://dx.doi.org/10.3389/fmolb.2023.1179343] [PMID: 37398551]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy